IsoRay Medical Inc. will feature its new brand campaign for its existing proprietary Cesium-131 prostate cancer brachytherapy seed at ASTRO 2007.
Under the name Proxcelan, IsoRay Medical Inc. is expanding the marketing of its Cesium-131 seeds used in low dose radiation (LDR) permanent brachytherapy for prostate cancer. The reportedly fast-acting, high energy medical isotope has demonstrated strong clinical results and is being heralded as the first leap forward in seed brachytherapy in 20 years.
Several abstracts are expected to be presented at the 2007 ASTRO meeting focusing on the therapeutic benefits of Proxcelan.
According to IsoRay, Proxcelan offers advantages over other isotopes. Available in leading facilities across the United States, it delivers its therapeutic radiation faster than other isotope seeds, Palladium-103 and Iodine-125, and at a reduced risk to patients when compared to surgery. Due to its unique characteristics, Proxcelan patients receive a higher initial dosage of radiation that attacks and kills cancer cells quickly. Its short half-life means that radiation leaves the body sooner than Iodine-125 and Palladium-103.